1. Home
  2. SBS vs UTHR Comparison

SBS vs UTHR Comparison

Compare SBS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Companhia de saneamento Basico

SBS

Companhia de saneamento Basico

HOLD

Current Price

$25.12

Market Cap

18.4B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBS
UTHR
Founded
1954
1996
Country
Brazil
United States
Employees
N/A
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4B
20.3B
IPO Year
2002
1999

Fundamental Metrics

Financial Performance
Metric
SBS
UTHR
Price
$25.12
$488.92
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$495.08
AVG Volume (30 Days)
1.2M
424.3K
Earning Date
11-10-2025
10-29-2025
Dividend Yield
2.18%
N/A
EPS Growth
N/A
16.08
EPS
1.98
26.38
Revenue
$6,502,517,346.00
$3,128,400,000.00
Revenue This Year
N/A
$13.64
Revenue Next Year
$14.38
$5.78
P/E Ratio
$12.82
$18.55
Revenue Growth
N/A
13.50
52 Week Low
$13.87
$266.98
52 Week High
$27.25
$492.62

Technical Indicators

Market Signals
Indicator
SBS
UTHR
Relative Strength Index (RSI) 44.39 68.10
Support Level $26.53 $470.13
Resistance Level $27.08 $492.62
Average True Range (ATR) 0.60 10.72
MACD -0.09 -0.53
Stochastic Oscillator 4.96 89.55

Price Performance

Historical Comparison
SBS
UTHR

About SBS Companhia de saneamento Basico

Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: